Prediction of docetaxel response in human breast cancer by gene expression profiling

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 422-431

  Iwao Koizumi, Kyoko ^a   Matoba, Ryo ^a   Ueno, Noriko ^a   Kim, Seung Jin ^a   Ando, Akiko ^a   Miyoshi, Yasuo ^a   Maeda, Eisaku ^a   Noguchi, Shinzaburo ^a   Kato, Kikuya ^a  

^a NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GLUTATHIONE TRANSFERASE; PEROXIREDOXIN; THIOREDOXIN; ANTINEOPLASTIC AGENT; DNA; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR VOLUME; UNINDEXED SEQUENCE; BIOPSY; BREAST TUMOR; CLINICAL TRIAL; DECISION MAKING; DNA MICROARRAY; FORECASTING; GENETICS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOPSY; BREAST NEOPLASMS; DECISION MAKING; DNA, NEOPLASM; FEMALE; FORECASTING; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; TAXOIDS; TREATMENT OUTCOME;

EID: 14544268597     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.078     Document Type: Article

References (33)

1. Ringel I, Horwitz SB: Studies with RP56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291, 1991
2. Goble S, Bear HD: Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: The potential and the questions. Surg Clin North Am 83:943-971, 2003
3. Egawa C, Miyoshi Y, Takamura Y, et al: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer, Int J Cancer 95:255-259, 2001
4. Hasegawa S, Miyoshi Y, Egawa C, et al: Mutational analysis of the class I beta-tubulin gene in human breast cancer, Int J Cancer 101:46-51, 2002
5. Burkhart CA, Kavallaris M, Horwitz SB: The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471: O1-O9, 2001
6. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
7. Iwao K, Matoba R, Ueno N, et al: Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum Mol Genet 11:199-206, 2002
8. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
9. ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
10. Heys SD, Hutcheon AW, Sarkar TK, et al: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3:S69-S74, 2002 (suppl 2)
11. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
12. Kato K: Adaptor-tagged competitive PCR: A novel method for measuring relative gene expression. Nucleic Acids Res 25:4694-4696, 1997
13. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537, 1999
14. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002
15. Furey TS, Cristianini N, Duffy N, et al: Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16:906-914, 2000
16. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 85:289-300, 1995
17. Muro S, Takemasa I, Oba S, et al: Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. Genome Biol 4:R21, 2003
18. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 77:1561-1565, 1980
19. Stein CA: Mechanisms of action of taxanes in prostate cancer. Semin Oncol 26:3-7, 1999
20. Dan S, Tsunoda T, Kitahara O, et al: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62:1139-1147, 2002
21. Gordon GJ, Jensen RV, Hsiao LL, et al: Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 95:598-605, 2003
22. Holland MJ: Transcript abundance in yeast varies over six orders of magnitude. J Biol Chem 277:14363-14366, 2002
23. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21:4165-4174, 2003
24. Filomeni G, Rotilio G, Ciriolo MR: Cell signaling and the glutathione redox system. Biochem Pharmacol 64:1057-1064, 2002
25. Arner ES, Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102-6109, 2000
26. Nakamura H, Nakamura K, Yodoi J: Redox regulation of cellular activation. Annu Rev Immunol 15:351-369, 1997
27. Ban N, Takahashi Y, Takayama T, et al: Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, rnelphalan, and etoposide. Cancer Res 56:3577-3582, 1996
28. Bai F, Nakanishi Y, Kawasaki M, et al: Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma. Cancer 78:416-421, 1996
29. Shiga H, Heath EI, Rasmussen AA, et al: Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5:4097-4104, 1999
30. Yokomizo A, Ono M, Nanri H, et al: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55:4293-4296, 1995
31. Sasada T, Iwata S, Sato N, et al: Redox control of resistance to cis-diarnminedichloroplatinum (II) (CDDP): Protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97:2268-2276, 1996
32. Kahlos K, Soini Y, Saily M, et al: Upregulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95:198-204, 2001
33. Oblong JE, Chantier EL, Gallegos A, et al: Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemother Pharmacol 34:434-438, 1994